Drug Pricing
Our work in Drug Pricing
-
Medicare Coverage of Weight Loss Drugs Could Save the U.S. Billions of Dollars
The new weight loss drugs work, and represent huge value in treating obesity. Even though they are expensive, broader access to them via Medicare would end up saving the U.S. money.
Categorized in -
Medicare Part D Plans Increased Restrictions on Drug Coverage
Medicare Part D plans excluded more compounds from coverage or subjected more of them to review before patients can access treatments, USC researchers found.
Categorized in -
Medicare Part D Plans Greatly Increased Utilization Restrictions On Prescription Drugs, 2011–20
Part D plans became significantly more restrictive over time, rising from an average of 31.9 percent of compounds restricted in 2011 to 44.4 percent restricted in 2020.
Categorized in -
Pharmaceutical Pricing That Balances Innovation and Affordability for Patients with Rare Diseases
Alternative financing mechanisms for drugs that deliver significant long-term value for patients could strike a balance between encouraging innovation and accessibility.
-
Knowing Actual Prices Will Help HHS Set the Maximum Fair Price under the Inflation Reduction Act
Requiring data on actual net costs will improve negotiations over the “maximum fair price” for select drugs under Medicare.
Categorized in -
Ensuring Affordable and Valuable Pharmaceutical Innovation for Americans
Aligning drug prices with the actual value provided to patients stimulates innovation that benefits patients and discourages innovation that does not.
-
A Spoonful of Sugar Makes the Medicine Go Down
CVS said its 9,500 pharmacies soon will be reimbursed by health insurers and other payers for the cost of the drugs plus a limited markup. That sounds like a simplification of drug pricing. But for vertically integrated CVS Health, revenue will shift from its pharmacy benefits division (CVS Caremark) to another (CVS Pharmacy). The move may also be an attempt to defuse growing political pressure to regulate the PBM industry.
Categorized in -
Response to Sen. Cassidy’s Request for Information on Improving Americans’ Access to Gene Therapies
Schaeffer experts submitted a comment letter responding to a request for information from stakeholders about improving access to cell and gene therapies for ultra-rare diseases.
Categorized in -
The Inflation Reduction Act’s Harms Go Beyond Drug Pricing — They’re Threatening Your Medicare
The IRA threatens to deliver disaster across the entire innovation, financing and distribution system for prescription drugs.
Categorized in -
Why Does the Inflation Reduction Act Exclude Expensive Cancer Treatments in Price Negotiations?
The IRA negotiation provisions will have limited impact on cancer drug prices and will likely leave most patients with cancer exposed to high drug costs.
Categorized in